Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sofian M Tijono"'
Autor:
Sofian M Tijono, Brian D. Palmer, Petr Tomek, Jack U. Flanagan, Kimiora Henare, Swarna Gamage, Lukas Braun, Lai-Ming Ching
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1090 (2022)
Indoleamine 2, 3-dioxygenase 1 (IDO1) is commonly expressed by cancers as a mechanism for evading the immune system. Preclinical and clinical studies have indicated the potential of combining IDO1 inhibitors with immune therapies for the treatment of
Externí odkaz:
https://doaj.org/article/825ca3c7919f46be88a46084f90de0f0
Autor:
Romy Brauer, Liang-Chuan S. Wang, See-Tarn Woon, David J.A. Bridewell, Kimiora Henare, Dieter Malinger, Brian D. Palmer, Stefanie N. Vogel, Claudine Kieda, Sofian M. Tijono, Lai-Ming Ching
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 9, Pp 755-765 (2010)
The signaling pathway(s) and molecular target(s) for 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a tumor vascular disrupting agent in late stages of clinical development, are still undefined. As an approach toward identifying potential targets for
Externí odkaz:
https://doaj.org/article/baf727a07c2246b887a6ea00cdd7b610
Autor:
Liang-Chuan S. Wang, Lotte Thomsen, Rachel Sutherland, Charu B. Reddy, Sofian M. Tijono, Chun-Jen J. Chen, Catherine E. Angel, P. Rod Dunbar, Lai-Ming Ching
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 11, Iss 8, Pp 793-803 (2009)
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DM
Externí odkaz:
https://doaj.org/article/fb3f4ca07b2445e0a76c426d340caa9c
Autor:
Nishi Karunasinghe, Sue Osborne, Tiffany Schwass, Jonathan Masters, Karen S. Bishop, Shuotun Zhu, Roger Huang, Charis Brown, Ross Lawrenson, Alice Wang, Christine Keven, Lindsay D. Plank, Sofian M. Tijono, Michael Holmes, Lynnette R. Ferguson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) results in accelerated bone loss and increased risk of bone fracture. The aim of the present study was to evaluate serum bone markers—sclerostin, Dickkopf-1 (DKK-1) and osteoprot
Autor:
Petr Tomek, Brian D. Palmer, Jack U. Flanagan, Lai-Ming Ching, Rossella Capochiani de Iudicibus, Sofian M. Tijono
Publikováno v:
Bioorganic & Medicinal Chemistry. 39:116160
The expression of tryptophan catabolising enzyme indoleamine 2,3-dioxygenase 1 (IDO1) or tryptophan 2,3-dioxygenase 2 (TDO2) in cancers is associated with suppressed immunity and poor patient prognosis. Results from human clinical trials of IDO1 inhi
Autor:
Sofian M. Tijono, Ailsa L. McGregor, Lai-Ming Ching, Raymond Yung, Vahid Seyfoddin, Bronwen Connor, Christopher P. Guise
Publikováno v:
Cancer Chemotherapy and Pharmacology. 73:639-649
Glioblastomas are amongst the most highly vascularised tumours, and the pursuit of anti-angiogenic approaches such as bevacizumab has provided short-term benefits. The purpose of this study was to determine whether the vascular-disrupting agent, dime
Autor:
Sai Parng S Fung, Sofian M. Tijono, Jack U. Flanagan, Joanne F. Jamie, Brian D. Palmer, Lai-Ming Ching, Christopher J. Squire, Haiyan Wang, Petr Tomek, David J. A. Bridewell
Publikováno v:
Bioorganic & Medicinal Chemistry. 21:7595-7603
Screening of a fragment library identified 2-hydrazinobenzothiazole as a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme expressed by tumours that suppresses the immune system. Spectroscopic studies indicated that 2-hydrazinobenzo
Autor:
K Guo, L-M Ching, L-C S Wang, Kimiora Henare, Sofian M. Tijono, Brian D. Palmer, Steven M. Albelda
Publikováno v:
British Journal of Cancer
Background: Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were so promising.
Autor:
Li Wang, Sofian M. Tijono, L. L. Thomsen, Peter Dunbar, Cristin G. Print, Chun-Jen J. Chen, Lai-Ming Ching, L-Cs Wang, Kimiora Henare, Sintia Winkler
Publikováno v:
British Journal of Cancer
Background: The non-malignant cells of the tumour stroma have a critical role in tumour biology. Studies dissecting the interplay between cancer cells and stromal cells are required to further our understanding of tumour progression and methods of in
Publikováno v:
Cancer Research. 77:4691-4691
The functional plasticity of macrophages and their ability to support tumour growth or promote potent antitumor immunity make them an attractive target cancer therapy. Macrophages have been implicated in the complex antitumor activity of murine STING